Aipeng Medical Signs Strategic Cooperation Agreement with Platinum Pain Physician Group to Advance Cancer Pain Management

Source: China Securities Journal · CS.com.cn

China Securities Network (Reporter Li Lanjun) Recently, Aipeng Medical and Botong Pain Doctors Group signed a strategic cooperation agreement. Leveraging Aipeng Medical's leading technological advantages and robust R&D capabilities in the field of pain management, combined with Botong Pain Doctors Group's extensive clinical practice and management experience in cancer pain, the two parties will conduct extensive cooperation in the standardized and scientific management of refractory cancer pain, jointly promoting the development of China's pain healthcare sector.

Wang Ningyu, Chairman of Aipeng Medical, stated: “For cancer patients, cancer pain compounds their existing suffering, subjecting them to severe physical and psychological distress. We hope this collaboration will better leverage our respective strengths to provide scientific and standardized management of cancer pain through comprehensive products and services, ultimately benefiting a vast number of cancer patients.”

Wang Jiejun, founder of the Botong Pain Doctor Group, stated that the two parties will engage in multi-faceted cooperation, including but not limited to commercial collaboration, establishment of model hospitals, innovative research and workflow development, data sharing, and industry-clinical-research translation. It is anticipated that as this collaboration deepens, it will undoubtedly play a positive role in enhancing the scientific management of cancer pain, improving patients' quality of life and treatment outcomes, and advancing cancer control initiatives in China.

Wang Kun, Chief Expert of the Botong Pain Physicians Group, stated: “Cancer pain control is not only crucial to the quality of life for a vast number of patients, but pain treatment is also an indispensable component of the entire standardized cancer treatment process. We look forward to exploring more innovative cancer pain management service models through this collaboration, to help address the challenge of refractory cancer pain.”

It is reported that through this collaboration, both parties will jointly explore the development direction of standardized and scientific management for refractory cancer pain, alongside innovative research and process development. The partnership aims to provide patients with refractory cancer pain and healthcare institutions with a more comprehensive, end-to-end product and service system from hospital to home. Additionally, both parties will co-establish a demonstration management base for refractory cancer pain to promote the advancement of standardized management for this condition.